Cargando…

A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma

Detalles Bibliográficos
Autor principal: Kim, Seok Jin
Formato: Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065630/
https://www.ncbi.nlm.nih.gov/pubmed/21461307
http://dx.doi.org/10.5045/kjh.2011.46.1.57
_version_ 1782201006086422528
author Kim, Seok Jin
author_facet Kim, Seok Jin
author_sort Kim, Seok Jin
collection PubMed
description
format Text
id pubmed-3065630
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-30656302011-03-31 A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma Kim, Seok Jin Korean J Hematol Letter to the Editor Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2011-03 2011-03-15 /pmc/articles/PMC3065630/ /pubmed/21461307 http://dx.doi.org/10.5045/kjh.2011.46.1.57 Text en © 2011 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Kim, Seok Jin
A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
title A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
title_full A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
title_fullStr A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
title_full_unstemmed A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
title_short A therapeutic dilemma between the two "R"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large B-cell lymphoma
title_sort therapeutic dilemma between the two "r"s: additional rituximab or radiotherapy for limited, non-bulky diffuse large b-cell lymphoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065630/
https://www.ncbi.nlm.nih.gov/pubmed/21461307
http://dx.doi.org/10.5045/kjh.2011.46.1.57
work_keys_str_mv AT kimseokjin atherapeuticdilemmabetweenthetworsadditionalrituximaborradiotherapyforlimitednonbulkydiffuselargebcelllymphoma
AT kimseokjin therapeuticdilemmabetweenthetworsadditionalrituximaborradiotherapyforlimitednonbulkydiffuselargebcelllymphoma